[8-(1-ethyl-propoxy)-4-methyl-3,4-dihydro-quinazolin-2-yl]-methyl-amine | 918136-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: [8-(1-ethyl-propoxy)-4-methyl-3,4-dihydro-quinazolin-2-yl]-methyl-amine
• 英文别名: N,4-Dimethyl-8-[(pentan-3-yl)oxy]-1,4-dihydroquinazolin-2-amine；N,4-dimethyl-8-pentan-3-yloxy-3,4-dihydro-1H-quinazolin-2-imine
• CAS: 918136-47-7
• 化学式: C₁₅H₂₃N₃O
• 分子量: 261.367
• InChiKey: IZUYCIMDINTWDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  45.6
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 8-Alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines
  申请人：Alanine Alexander

  公开号：US20060293350A1

  公开（公告）日：2006-12-28

  The present invention relates to compounds of formula wherein R 1 , R 2 , R 3 , and n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT 5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome.

  本发明涉及具有式的化合物其中R1、R2、R3和n如规范中所述，以及其药用可接受的酸盐。式I的化合物可用于治疗与5-HT5A受体拮抗剂相关的疾病，包括抑郁症、焦虑障碍、精神分裂症、恐慌障碍、广场恐惧症、社交恐惧症、强迫性障碍、创伤后应激障碍、疼痛、记忆障碍、进食行为障碍、性功能障碍、睡眠障碍、戒除药物滥用、帕金森病等运动障碍、帕金森病痴呆、神经精神药物引起的帕金森症和迟发性运动障碍，以及其他精神障碍和胃肠道障碍，如肠易激综合征。
• 8-ALK0XY-4-METHYL-3, 4-DIHYDR0-QUINAZ0LIN-2-YL AMINES AND THEIR USE AS 5-HT5A RECEPTOR LIGANDS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1899307B1

  公开（公告）日：2010-06-30
• US7790733B2
  申请人：——

  公开号：US7790733B2

  公开（公告）日：2010-09-07